Go to:
Logótipo
Você está em: Start > Publications > View > A Real-World Study Reporting the Use of Foundation Medicine® Testing in Portugal
Map of Premises
Principal
Publication

A Real-World Study Reporting the Use of Foundation Medicine® Testing in Portugal

Title
A Real-World Study Reporting the Use of Foundation Medicine® Testing in Portugal
Type
Article in International Scientific Journal
Year
2023
Authors
Pinto, R
(Author)
Other
The person does not belong to the institution. The person does not belong to the institution. The person does not belong to the institution. Without AUTHENTICUS Without ORCID
Fernando Schmitt
(Author)
FMUP
View Personal Page You do not have permissions to view the institutional email. Search for Participant Publications View Authenticus page View ORCID page
Journal
The Journal is awaiting validation by the Administrative Services.
Vol. 4
Pages: 156-165
ISSN: 2673-5261
Indexing
Publicação em ISI Web of Knowledge ISI Web of Knowledge - 0 Citations
Publicação em Scopus Scopus - 0 Citations
Other information
Authenticus ID: P-010-481
Resumo (PT):
Abstract (EN): Foundation Medicine (R) testing is a next-generation sequence (NGS)-based platform that allows clinicians to obtain the comprehensive genomic profiling (CGP) of several cancers. By using NGS approaches, relevant genomic alterations can be identified in a short timeframe, providing guidance to diagnostic and therapeutic decisions. This study reports the implementation of three commercially available Foundation Medicine (R) tests in a Portuguese institution and explores the genomic alterations identified. Data obtained from 72 patients tested with Foundation Medicine (R) between July 2017 and December 2020 were analysed retrospectively. A total of 290 gene alterations were identified, and TP53 was the gene most frequently altered. Among the 67 successfully profiled samples, 37.3% presented a potentially actionable variation. Breast carcinoma represented the most frequent tumour-carrying variation that can be targeted using currently approved drugs. A limited number of potentially actionable variants using approved drugs was found in this study; however, the genomic information provided by Foundation Medicine (R) may help clinicians in directing cancer patients into clinical trials or to off-label treatments.
Language: English
Type (Professor's evaluation): Scientific
No. of pages: 10
Documents
We could not find any documents associated to the publication.
Related Publications

Of the same authors

Prognostic value of stromal tumour infiltrating lymphocytes and programmed cell death-ligand 1 expression in breast cancer (2017)
Article in International Scientific Journal
Polonia, A; Pinto, R; Cameselle Teijeiro, JF; Fernando Schmitt; Paredes, J
Morphological control for molecular testing: a practical approach (2021)
Article in International Scientific Journal
Gullo, I; Marques, A; Pinto, R; Cirnes, L; Fernando Schmitt
How the COVID-19 Pandemic Impacted Oncological Molecular Diagnosis: A Picture from a National Reference Center for Molecular Pathology (2020)
Article in International Scientific Journal
Pinto, D; Cirnes, L; Pinto, R; Pina, MJ; Troncone, G; Fernando Schmitt

Of the same journal

The Multifaceted Profile of Thyroid Disease in the Background of DICER1 Germline and Somatic Mutations: Then, Now and Future Perspectives (2022)
Article in International Scientific Journal
Canberk S.; Correia M.; Lima A.R.; Bongiovanni M.; Sobrinho-Simões M; Soares, P; Maximo, V
Optimal Assessment of Metastatic Breast Carcinoma: The Value of Cytopathology Combined with Molecular Analysis (2022)
Article in International Scientific Journal
Souza da Silva, R; Fernando Schmitt
Recommend this page Top
Copyright 1996-2025 © Faculdade de Medicina Dentária da Universidade do Porto  I Terms and Conditions  I Acessibility  I Index A-Z
Page created on: 2025-08-12 at 01:49:54 | Privacy Policy | Personal Data Protection Policy | Whistleblowing | Electronic Yellow Book